What is Pseudomyxoma Peritonei

Pseudomyxoma peritonei (PMP) is a rare, slow-growing condition characterized by the accumulation of mucinous (gelatinous) fluid within the abdomen, typically originating from a ruptured tumor in the appendix. While the condition is technically a malignancy, it is often described as a "borderline" or low-grade tumor that spreads throughout the peritoneal cavity rather than through the bloodstream.

What exactly is Pseudomyxoma Peritonei?

Pseudomyxoma peritonei is a rare clinical syndrome where mucin-producing cells deposit jelly-like material across the lining of the abdominal cavity, known as the peritoneum. This condition is most frequently caused by a low-grade appendiceal mucinous neoplasm. As the abdominal cavity fills with this mucin, it can compress internal organs, leading to significant discomfort and functional challenges within the digestive system.

Who is typically affected by Pseudomyxoma Peritonei?

Pseudomyxoma peritonei is exceptionally rare, with an estimated incidence of approximately 1 to 2 cases per million people each year. It is most commonly diagnosed in adults between the ages of 40 and 60. While it can affect both men and women, clinical literature suggests a slightly higher prevalence in women. Currently, 110 people with Pseudomyxoma peritonei have joined the DiseaseMaps.org community to share their experiences and support one another.

How does Pseudomyxoma Peritonei differ from other cancers?

Unlike many common cancers that metastasize through the lymphatic system or bloodstream, Pseudomyxoma peritonei typically spreads by "seeding" the surface of the abdominal organs. Key differentiating factors include:

• Slow Progression: It is generally a slow-growing disease that may remain asymptomatic for years.


• Mucin Accumulation: The primary clinical concern is the physical "mass effect" of the mucin, rather than aggressive tissue invasion.


• Treatment Focus: Management often involves specialized surgical techniques, such as cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC), rather than systemic chemotherapy alone.

Next steps

• Consult a surgical oncologist who specializes in peritoneal surface malignancies.


• Request a referral to a high-volume center that performs HIPEC procedures.


• Connect with the 110 members of the Pseudomyxoma peritonei community at DiseaseMaps.org for peer support.


• Keep a detailed symptom diary to discuss with your multidisciplinary care team.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

• Orphanet: Pseudomyxoma peritonei (ORPHA: 760)


• NIH Genetic and Rare Diseases Information Center (GARD)


• PMP Pals (Patient support and advocacy foundation)


• National Cancer Institute (NCI) - Appendix Cancer and PMP resources